Adverse event reporting information can be found at the bottom of the page

Chronic Obstructive Pulmonary Disease (COPD)

You are here: / COPD

WockAIR® can be used in such patients who have FEV1 <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy.2

Bronchodilators (beta-2 agonists and muscarinic antagonists) are central to the management of COPD and are usually given on a regular basis to control symptoms. Use of ICS in stable COPD tends to be reserved for those with moderate to severe disease, where ICS/LABA combination has been shown to be more effective than either component alone in improving lung function, health status and reducing exacerbations. However this needs to be balanced against the increased risk of pneumonia.1 

GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines support use of ICS in COPD when there is a history of hospitalisations for COPD exacerbations, or ≥2 moderate exacerbations per year.1

GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines support use of ICS in COPD when there is a history of hospitalisations for COPD exacerbations, or ≥2 moderate exacerbations per year, or when eosinophil counts are high (>300 cells/µl). However they should not be used in patients with a history of repeated pneumonia events.1

Currently NICE suggests that ICS/LABA should be considered in people who;3

  • have spirometrically confirmed COPD and
  • have asthmatic features/features suggesting steroid responsiveness and
  • remain breathless or have exacerbations despite:
    • having used or been offered treatment for tobacco dependence if they smoke and
    • optimised non-pharmacological management and relevant vaccinations and
    • using a short-acting bronchodilator.

For the full NICE guidelines on COPD, visit NICE.org.uk

WockAIR Package Shot

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to Wockhardt UK. Please contact us or email us at drug.safety@wockhardt.co.uk

REFERENCES

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and prevention of chronic obstructive pulmonary disease 2021 report. Available at https://goldcopd.org Accessed February 2024

2. WockAIR® SmPC

3. NICE pathways Stable COPD:inhaled therapy August 2020 Available at https://pathways.nice.org.uk/pathways/chronic-obstructive-pulmonary-disease Accessed May 2021

This site is intended for UK Healthcare Professionals.
Contact Us | Cookies and Privacy Policy | Terms of and Conditions of Use | Sitemap | PIL | Pharmacovigilance Privacy Notice
Job code: AIR06/25 July 2025